Longevity ⇒ mTOR inhibition Phase 3 clinical trial fails.

[AlbertY]

resTORbio Announces That the Phase 3 PROTECTOR 1 Trial of RTB101 in Clinically Symptomatic Respiratory Illness Did Not Meet the Primary Endpoint

RTB101 were inhibiting mTORC1, to minimize side effects of whole TOR inhibition, and targeting respiratory illness.

https://ir.restorbio.com/news-releases/ ... linically/

[Drdavid]

This is disappointing but I hope some of the other research regarding mTor inhibition will provide satisfying results especially in the Parkinson diagnosis catagory.
Thank you for sharing this research

[canadahealthy]

Failure is disappointing, but the scientific method is paving the way for accurate, successful treatments.

This is patently obvious to many people here, but some times anecdotal evidence is not evidence at all - it needs the trials.